0001487371-19-000008.txt : 20190122
0001487371-19-000008.hdr.sgml : 20190122
20190122192722
ACCESSION NUMBER: 0001487371-19-000008
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190117
FILED AS OF DATE: 20190122
DATE AS OF CHANGE: 20190122
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mitchell Brian Andrew
CENTRAL INDEX KEY: 0001707237
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34753
FILM NUMBER: 19536353
MAIL ADDRESS:
STREET 1: 5964 LA PLACE COURT
CITY: CARLSBAD
STATE: CA
ZIP: 92008
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: GenMark Diagnostics, Inc.
CENTRAL INDEX KEY: 0001487371
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 272053069
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5964 LA PLACE COURT
CITY: CARLSBAD
STATE: CA
ZIP: 92008
BUSINESS PHONE: (760) 448-4300
MAIL ADDRESS:
STREET 1: 5964 LA PLACE COURT
CITY: CARLSBAD
STATE: CA
ZIP: 92008
4
1
wf-form4_154820322595280.xml
FORM 4
X0306
4
2019-01-17
0
0001487371
GenMark Diagnostics, Inc.
GNMK
0001707237
Mitchell Brian Andrew
5964 LA PLACE COURT
CARLSBAD
CA
92008
0
1
0
0
SVP, Operations
Common Stock
2019-01-17
4
M
0
9600
0
A
150469
D
Market Stock Units
0.0
2019-01-17
4
M
0
9600
0
A
Common Stock
9600.0
16650
D
Each market stock unit ("MSU") represents the contingent right to receive, following vesting, between 0% and 200% of one share of the Issuer's common stock, subject to the level of achievement of applicable performance conditions. The resulting number of shares acquired upon vesting of the MSUs, if any, is based on the Issuer's total shareholder return for each performance period as compared to the NASDAQ Composite Index.
The MSUs vest in three equal installments, on each of December 31, 2018, December 31, 2019, and December 31, 2020; provided that, at the end of the second and third performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the NASDAQ Composite Index.
/s/ Eric Stier, Attorney-in-fact
2019-01-22